JP2024531685A5 - - Google Patents

Info

Publication number
JP2024531685A5
JP2024531685A5 JP2024515840A JP2024515840A JP2024531685A5 JP 2024531685 A5 JP2024531685 A5 JP 2024531685A5 JP 2024515840 A JP2024515840 A JP 2024515840A JP 2024515840 A JP2024515840 A JP 2024515840A JP 2024531685 A5 JP2024531685 A5 JP 2024531685A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
apomorphine
tgf
composition according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531685A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/075763 external-priority patent/WO2023039345A2/en
Publication of JP2024531685A publication Critical patent/JP2024531685A/ja
Publication of JP2024531685A5 publication Critical patent/JP2024531685A5/ja
Pending legal-status Critical Current

Links

JP2024515840A 2021-09-12 2022-08-31 神経障害の処置 Pending JP2024531685A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163243175P 2021-09-12 2021-09-12
US202163243177P 2021-09-12 2021-09-12
US63/243,175 2021-09-12
US63/243,177 2021-09-12
PCT/US2022/075763 WO2023039345A2 (en) 2021-09-12 2022-08-31 Treatment of neurological disorders

Publications (2)

Publication Number Publication Date
JP2024531685A JP2024531685A (ja) 2024-08-29
JP2024531685A5 true JP2024531685A5 (https=) 2025-09-08

Family

ID=85506869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515840A Pending JP2024531685A (ja) 2021-09-12 2022-08-31 神経障害の処置

Country Status (8)

Country Link
US (1) US20240216359A1 (https=)
EP (1) EP4398908A4 (https=)
JP (1) JP2024531685A (https=)
KR (1) KR20240069750A (https=)
AU (1) AU2022341090B2 (https=)
CA (1) CA3231407A1 (https=)
MX (1) MX2024002875A (https=)
WO (1) WO2023039345A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2025014637A (es) * 2023-06-05 2026-02-03 Gmp Biotechnology Ltd Productos terapeuticos de tgfb2-irf5 para cancer
WO2025071299A1 (ko) * 2023-09-27 2025-04-03 아주대학교산학협력단 C-fos 억제제의 우울/불안 장애를 동반한 파킨슨병 치료 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE290864T1 (de) * 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
PL1716235T3 (pl) * 2004-02-09 2012-11-30 Ulrich Bogdahn Inhibitory przekazywania sygnałów TGF-R do leczenia zaburzeń ośrodkowego układu nerwowego
NZ703341A (en) * 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
US20180280465A1 (en) * 2015-09-28 2018-10-04 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
US9758786B2 (en) * 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2021186396A2 (en) * 2020-03-18 2021-09-23 Oncotelic Inc. Tgf-beta inhibition, agents and composition therefor
AU2021102241A4 (en) * 2021-04-29 2021-06-17 University Of Macau Application of Artemisinin Compounds in Preparation of Drug for Preventing and Treating Brain Diseases

Similar Documents

Publication Publication Date Title
AU2016371598B2 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
JP7107624B2 (ja) エダラボンの経口又は胃内投与を含む処置
JP2024531685A5 (https=)
KR20180100309A (ko) 데옥시콜산 및 이의 염을 사용한 축적된 지방의 치료 방법
US20240216359A1 (en) Treatment of neurological disorders
KR20180066071A (ko) 비점막 투여용 의약 조성물
JP2011144111A (ja) 軸性近視の予防または治療剤
US20160082026A1 (en) Ganglioside Transmucosal Formulations
CN110461325A (zh) 包括口服或胃部施用依达拉奉的治疗
EP4420660A1 (en) Use of edaravone in treatment of autism spectrum disorder
CN112516091B (zh) 一种地塞米松磷酸钠冻干粉针剂
JP2018108993A (ja) 注腸剤
CN118252833A (zh) Vofopitant用于治疗肺纤维化的用途
EP3215125B1 (en) Compositions comprising finafloxacin and tris
CA3149980A1 (en) Therapeutic methods and uses thereof
US11858908B2 (en) Compositions and methods for inhibiting IDO1
CN100544729C (zh) 供静脉用异甘草酸镁制剂及其制备方法
US20230031188A1 (en) Methods of Treating Skin Diseases
KR20240025512A (ko) 건선의 치료 방법
HK40113386A (zh) 神经病症的治疗
CN104427982A (zh) 治疗炎性和免疫障碍的组合物
CA2554045A1 (en) Method for treating erectile dysfunction
JPH0892089A (ja) ドライバジャイナ治療剤
CN1909905A (zh) 治疗勃起功能障碍的方法